Physician profile
James E Lynch
NPI 1366485229
$3,091.25
in general payments reported to CMS, 2019-2025
31 companies · $155 in 2025
The $155 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,231 · 2020: $15.55 · 2021: $321 · 2022: $111 · 2023: $92.37 · 2024: $165 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $413.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $633.12 | 2021-2025 | |
| Amgen INC. | $258.76 | 2019 | |
| Tersera Therapeutics LLC | $256.16 | 2019 | |
| Pfizer INC. | $219.45 | 2019-2020 | |
| Lilly USA, LLC | $212.41 | 2019 | |
| Mdd US Operations, LLC | $169.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $156.83 | 2019-2024 | Trintellix |
| Collegium Pharmaceutical, INC. | $140.09 | 2019 | |
| Biodelivery Sciences International, INC. | $128.38 | 2019 | |
| Horizon Therapeutics Plc | $125.96 | 2019 | |
| Janssen Pharmaceuticals, INC | $122.03 | 2024 | Spravato |
| Scilex Pharmaceuticals INC. | $118.79 | 2019 | |
| Sentynl Therapeutics, INC. | $75.89 | 2019 | |
| Medtronic USA, INC. | $65.45 | 2019 | |
| Orexo US, INC. | $59.04 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $48.32 | 2019 | |
| Pacira Therapeutics, INC. | $43.88 | 2019 | |
| Novo Nordisk INC | $38.25 | 2024-2025 | Rybelsus, Ozempic |
| Promius Pharma LLC | $29.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.15 | 2025 | Jardiance |
| Assertio Therapeutics, INC. | $23.71 | 2019 | |
| Zyla Life Sciences, INC. | $22.77 | 2019 | |
| Daiichi Sankyo INC. | $14.80 | 2019 | |
| Kaleo, INC. | $14.72 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.43 | 2019 | |
| Merck Sharp & Dohme LLC | $13.46 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $12.43 | 2019 | |
| Shionogi INC | $12.33 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.75 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.56 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.